An amino acid found in meat, nuts, and legumes activates an intestinal repair mechanism science hadn't previously known. Researchers at MIT's Koch Institute for Integrative Cancer Research discovered this while deliberately seeking a nutrition-based solution to one of cancer therapy's most common problems. Up to 80 percent of all chemotherapy patients develop inflammatory lining damage in the gut for which no active countermeasure existed until now.
What Is Cysteine?
Cysteine is a sulfur-containing amino acid the body produces in small amounts itself but obtains mostly from food. Good sources are animal products like meat, fish, and eggs, but also plant foods including legumes, nuts, and sunflower seeds. Cysteine was previously known mainly as a building block for glutathione, the body's primary antioxidant.
A research team led by MIT cancer biologist Ömer H. Yilmaz systematically tested all 20 protein amino acids for one property: the ability to rebuild intestinal lining after injury. Cysteine stood out clearly in these experiments. The results appeared in Nature.
From Amino Acid to Stem Cell Activation
The newly discovered pathway involves multiple steps the team sequentially decoded. When intestinal cells absorb cysteine, it gets enzymatically converted to coenzyme A (CoA). CD8 T-cells, an immune cell class normally known for killing virus-infected or cancerous cells, absorb this CoA. In this context, the T-cells produce the signaling molecule interleukin-22 (IL-22). IL-22 in turn activates intestinal stem cells, which then replace damaged cells.
In mouse models, animals on cysteine-rich diets showed markedly stronger regeneration of intestinal villi—the finger-like protrusions of lining where the body absorbs nutrients. When chemotherapy or radiation damages these villi, stubborn diarrheas, inflammation, and nutrient deficiency result, slowing overall healing.
Why This Particularly Matters for Cancer Patients
Chemotherapy and radiation deliberately target fast-dividing cells. The problem: intestinal lining also constantly renews and comes under fire. The resulting mucositis, inflammatory lining damage in the digestive tract, affects 40 to 80 percent of chemotherapy patients depending on protocol. In high-dose protocols before stem-cell transplants it strikes nearly everyone.
Previous support measures restrict themselves to symptom control: painkillers, nutrition counseling, electrolyte solutions. No active regeneration support existed. The MIT team sees cysteine-rich diet or targeted supplementation as a possible new approach that would be simple and cheap because cysteine already appears in everyday foods.
In Comparison: What Prior Gut-Healing Research Showed
Cysteine isn't the first substance tested for regeneration after gut damage. Glutamine, also an amino acid, has been studied since the 1990s as a protective agent for intestinal lining in cancer studies. Results stayed mixed: some trials showed reduced mucositis severity, others no effect. A core problem was the mechanism never being fully understood. The pathway now described with cysteine is far more precise than anything glutamine research ever identified.
Butyrate, a short-chain fatty acid gut bacteria produce from fiber, is another known intestinal lining protection mechanism. It strengthens the gut barrier and supplies intestinal epithelial cells substantial energy. Butyrate chiefly protects the colon, while the small intestine most affected by chemomucositis needs other mechanisms. Exactly here cysteine acts.
Three Hurdles Until Clinical Use
The path from mouse model to therapy standard is long. Three conditions must hold before cysteine embeds in cancer care protocols.
First, clinical trials in humans must show the mechanism works in the human intestine at therapeutically relevant doses. Mouse and human intestinal physiology diverge significantly in CD8 T-cell behavior and microbiome composition. The MIT team plans clinical pilots.
Second, optimal dosing must be determined. Very high cysteine can promote oxidative stress because it metabolizes into reactive sulfur compounds. In amino acids the border between helpful and harmful often runs narrow.
Third, it's unclear how well the mechanism works with severely weakened immune systems. Chemotherapy patients often have reduced CD8 T-cell counts forming potential bottlenecks in the described pathway. Planned human trials will clarify this.